merged_colon-cancer-blood-test-shield.txt
<question_number>1</question_number>
<answer>Its poor record of finding precancerous growths.</answer>

<question_number>2</question_number>
<answer>A colonoscopy.</answer>

<question_number>3</question_number>
<answer>It is simpler for patients, requiring only a blood sample that can be obtained at a doctor's office or commercial lab.</answer>

<question_number>4</question_number>
<answer>Its inability to find precancerous growths, which contradicts the typical goal of preventing cancer through removal of these growths.</answer>

<question_number>5</question_number>
<answer>The FDA advisory committee's recommendation for approval despite the test's limitations reflects a compromise between increasing screening rates and optimal cancer prevention.</answer>

<question_number>6</question_number>
<answer>The test's simplicity and ease of use align with the challenges faced by other screening methods, while its poor record of finding precancerous growths introduces a new limitation.</answer>

<question_number>7</question_number>
<answer>The test's inability to prevent cancer through removal of precancerous growths contradicts typical expectations for a cancer screening tool's preventive capabilities.</answer>

<question_number>8</question_number>
<answer>The test's simplicity and ease of use align with the challenges of current screening methods, while potentially creating a new obstacle in cancer prevention due to its limitations.</answer>

<question_number>9</question_number>
<answer>Its poor record of finding precancerous growths compared to other screening tests.</answer>

<question_number>10</question_number>
<answer>The committee recommended approval because the test may prompt people who forget or avoid colorectal cancer screening to be screened.</answer>